Terrapex (CEO Lee Gu), a subsidiary of Gradient, announced on the 24th that it has ended its participation in the global bio industry event, '2025 Bio International Convention (BIO USA)'.
At this event, Terapex presented the research results of its core pipeline, the next-generation EGFR inhibitor 'TRX-221', and actively discussed partnerships for technology transfer with a number of global pharmaceutical companies and foreign biotech companies.
TRX-221 is a 4th generation EGFR tyrosine kinase inhibitor (4th Generation EGFR-TKI) that inhibits the C797S mutation that causes EGFR mutation non-small cell lung cancer drug resistance, and is currently in the final stages of a phase 1 clinical dose escalation trial (Dose Escalation Study) in Korea.
Terapex discussed various aspects of its lung cancer treatment development strategy and differentiated positioning compared to competing pipelines, along with the interim clinical data of TRX-221. In particular, through one-on-one partnering meetings with major global big pharmas and emerging biotechs, in-depth discussions were held on technology transfer (L/O), joint development (Co-dev), and joint global clinical trials.
Terapex CEO Lee Gu said, “At this BIO USA, we had substantial technology transfer discussions with around 20 companies, including large global pharmaceutical companies. In particular, it was a meaningful opportunity to confirm that TRX-221 can establish itself as a new option for lung cancer treatment.” He continued, “Through this partnering, we will demonstrate Terapex’s R&D competitiveness and global market entry potential, and lay the foundation for future strategic collaboration.”
- See more related articles
You must be logged in to post a comment.